IKZF1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%.
Images
Key facts
- Cell type
Jurkat
- Species or organism
Human
- Tissue
Blood
- Knockout validation
Next Generation Sequencing, Western blot
Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%
Alternative names
CLL associated antigen KW 6, DNA-binding protein Ikaros, Hs.54452, IK1, IKAROS, IKAROS family zinc finger 1 (Ikaros), IKZF1_HUMAN, Ikaros (zinc finger protein), Ikaros family zinc finger protein 1, LYF1, Lymphoid transcription factor LyF-1, PRO0758, ZNFN1A1, Zinc finger protein subfamily 1A 1, Zinc finger protein subfamily 1A 1 (Ikaros), Zinc finger protein, subfamily 1A, member 1, hIk 1
What's included?
Recommended products
IKZF1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%.
Alternative names
CLL associated antigen KW 6, DNA-binding protein Ikaros, Hs.54452, IK1, IKAROS, IKAROS family zinc finger 1 (Ikaros), IKZF1_HUMAN, Ikaros (zinc finger protein), Ikaros family zinc finger protein 1, LYF1, Lymphoid transcription factor LyF-1, PRO0758, ZNFN1A1, Zinc finger protein subfamily 1A 1, Zinc finger protein subfamily 1A 1 (Ikaros), Zinc finger protein, subfamily 1A, member 1, hIk 1
Key facts
- Cell type
Jurkat
- Species or organism
Human
- Tissue
Blood
- Knockout validation
Next Generation Sequencing, Western blot
- Mutation description
Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%
- Disease
Non-Hodgkin Lymphoma
- Concentration
Properties
- Gene name
IKZF1
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Next Generation Sequencing, Western blot
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 1 US: 1
- Adherent/suspension
Suspension
- Gender
Male
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Ikaros also known as IKZF1 is a transcription factor. You also find it being referred to as the Ikaros protein or Ikaros code. It has a molecular mass of about 58-60 kDa. Ikaros expresses mostly in hematopoietic cells including precursors from which various blood cell types derive. It plays a significant role in regulating gene expression and cellular differentiation modulating the chromatin structure to control access to DNA.
- Biological function summary
Ikaros protein functions in the regulation of lymphoid cell development. It is a part of a chromatin-remodeling complex influencing chromatin accessibility. Through its zinc finger domains it binds to specific DNA sequences controlling genes necessary for lymphocyte differentiation and proliferation. Ikaros influences various cell types within the immune system especially affecting T and B cell development and also regulates cytokine receptor genes necessary for proper immune function.
- Pathways
The Ikaros protein is critical to lymphocyte signaling pathways particularly the JAK/STAT and NF-κB pathways. In these pathways Ikaros interacts with other transcription factors like GATA3 and STAT5 integrating signals that are important for immune cell function and development. This integration allows a coordinated response to extracellular signals ensuring effective immune responses or tolerance.
- Associated diseases and disorders
Ikaros is associated with leukemia and lymphomas. Alterations or mutations in ikaros gene can lead to misregulation of its target genes contributing to the development of these diseases by disturbing normal hematopoietic processes. Moreover its interaction with TAL1 protein is significant in certain leukemias where disturbances in the balance of their activities can lead to malignancies. Understanding Ikaros’s role provides insights for therapeutic approaches in these blood disorders.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Next Generation Sequencing - Human IKZF1 knockout Jurkat cell lysate (ab274978)
Knockout achieved by CRISPR/Cas9; X = 2 bp insertion, 1 bp insertion; Frameshift: 100%
Western blot - Human IKZF1 knockout Jurkat cell lysate (ab274978)
Lane 1: Wild-type Jurkat cell lysate 20 ug
Lane 2: IKZF1 knockout Jurkat cell lysate 20 ug
Lane 3: Daudi (Human Burkitt's lymphoma cell line) whole cell lysate 20 ug
Lane 4: HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate 20 ug
Lanes 1 - 4: Merged signal (red and green). Green - Anti-Ikaros antibody [EPR13790] ab191394 observed at 50-70 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
Anti-Ikaros antibody [EPR13790] ab191394 was shown to react with Ikaros in wild-type Jurkat cells in western blot with loss of signal observed in IKZF1 knockout cell line Human IKZF1 knockout Jurkat cell line ab274920 (knockout cell lysate ab274978). Wild-type and IKZF1 knockout Jurkat cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with Anti-Ikaros antibody [EPR13790] ab191394 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 10000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-Ikaros antibody [EPR13790] (Anti-Ikaros antibody [EPR13790] ab191394) at 1/10000 dilution
Lane 1: Wild-type Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg
Lane 2: IKZF1 knockout Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg
Lane 3: Daudi (Human Burkitt's lymphoma cell line) whole cell lysate at 20 µg
Lane 4: HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 57 kDa
Observed band size: 50-70 kDa
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com